Liang C - Search Results

1

Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity.

Liang C, Yuan X, Shen Z, Wang Y, Ding L. Liang C, et al. Mol Ther Oncolytics. 2022 Jan 10;24:577-584. doi: 10.1016/j.omto.2022.01.001. eCollection 2022 Mar 17. Mol Ther Oncolytics. 2022. PMID: 35252556 Free PMC article.

2

Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial.

Song Y, Wang J, Ren X, Jin J, Mao L, Liang C, Ding L, Yang L. Song Y, et al. Among authors: liang c. Chin J Cancer Res. 2021 Feb 28;33(1):103-114. doi: 10.21147/j.issn.1000-9604.2021.01.11. Chin J Cancer Res. 2021. PMID: 33707933 Free PMC article.

3

Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.

Pedersen KS, Grierson PM, Picus J, Lockhart AC, Roth BJ, Liu J, Morton A, Chan E, Huffman J, Liang C, Wang-Gillam A, Tan B. Pedersen KS, et al. Among authors: liang c. Invest New Drugs. 2021 Oct;39(5):1298-1305. doi: 10.1007/s10637-021-01093-7. Epub 2021 Mar 18. Invest New Drugs. 2021. PMID: 33738668 Clinical Trial.

4

Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors.

Bagegni NA, Park H, Kraft K, O-Toole M, Gao F, Waqar SN, Ratner L, Morgensztern D, Devarakonda S, Amin M, Baggstrom MQ, Liang C, Selvaggi G, Wang-Gillam A. Bagegni NA, et al. Among authors: liang c. Cancer Chemother Pharmacol. 2022 Apr;89(4):487-497. doi: 10.1007/s00280-022-04406-6. Epub 2022 Mar 5. Cancer Chemother Pharmacol. 2022. PMID: 35247086 Free PMC article. Clinical Trial.

5

A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers.

Meng L, Shu M, Chen Y, Yang D, He Q, Zhao H, Feng Z, Liang C, Yu K. Meng L, et al. Among authors: liang c. Cancer Biol Ther. 2014 Jun 1;15(6):721-34. doi: 10.4161/cbt.28409. Epub 2014 Mar 11. Cancer Biol Ther. 2014. PMID: 24618813 Free PMC article.

6

New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.

Di Paolo D, Yang D, Pastorino F, Emionite L, Cilli M, Daga A, Destafanis E, Di Fiore A, Piaggio F, Brignole C, Xu X, Liang C, Gibbons J, Ponzoni M, Perri P. Di Paolo D, et al. Among authors: liang c. Oncotarget. 2015 Oct 6;6(30):28774-89. doi: 10.18632/oncotarget.4342. Oncotarget. 2015. PMID: 26299615 Free PMC article.

7

Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.

Chen SM, Liu JL, Wang X, Liang C, Ding J, Meng LH. Chen SM, et al. Among authors: liang c. Biochem Pharmacol. 2012 May 1;83(9):1183-94. doi: 10.1016/j.bcp.2012.01.019. Epub 2012 Jan 26. Biochem Pharmacol. 2012. PMID: 22305748

8

Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors.

Bendell JC, Patel MR, Moore KN, Chua CC, Arkenau HT, Dukart G, Harrow K, Liang C. Bendell JC, et al. Among authors: liang c. Oncologist. 2019 Apr;24(4):455-e121. doi: 10.1634/theoncologist.2018-0740. Epub 2018 Nov 26. Oncologist. 2019. PMID: 30478190 Free PMC article. Clinical Trial.

9

EDDINet: Enhancing drug-drug interaction prediction via information flow and consensus constrained multi-graph contrastive learning.

Wang H, Zhuang L, Ding Y, Tiwari P, Liang C. Wang H, et al. Among authors: liang c. Artif Intell Med. 2024 Nov 20;159:103029. doi: 10.1016/j.artmed.2024.103029. Online ahead of print. Artif Intell Med. 2024. PMID: 39608043

10

Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma.

Guo J, Wu Q, Li H, Liang C, Dai J, Zhang S, Dai C, Zhang J, Wen Y, Yang W. Guo J, et al. Among authors: liang c. Front Immunol. 2024 Nov 13;15:1435934. doi: 10.3389/fimmu.2024.1435934. eCollection 2024. Front Immunol. 2024. PMID: 39606226 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10,675 results

Search Page

Filters